Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

180 Life Sciences stock

ATNF
US68236V1044
A2QJX5

Price

2.90
Today +/-
-0.03
Today %
-1.03 %
P

180 Life Sciences stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the 180 Life Sciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the 180 Life Sciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the 180 Life Sciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze 180 Life Sciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

180 Life Sciences Stock Price History

Date180 Life Sciences Price
11/8/20242.90 undefined
11/7/20242.93 undefined
11/6/20243.03 undefined
11/5/20243.17 undefined
11/4/20243.42 undefined
11/1/20243.74 undefined
10/31/20243.92 undefined
10/30/20243.93 undefined
10/29/20244.43 undefined
10/28/20244.23 undefined
10/25/20244.26 undefined
10/24/20243.88 undefined
10/23/20244.25 undefined
10/22/20244.69 undefined
10/21/20244.97 undefined
10/18/20245.03 undefined
10/17/20244.33 undefined
10/16/20246.47 undefined
10/15/20241.52 undefined
10/14/20241.36 undefined

180 Life Sciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into 180 Life Sciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by 180 Life Sciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects 180 Life Sciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of 180 Life Sciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into 180 Life Sciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing 180 Life Sciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on 180 Life Sciences’s growth potential.

180 Life Sciences Revenue, EBIT and net profit per share

Date180 Life Sciences Revenue180 Life Sciences EBIT180 Life Sciences Net Income
2030e223.57 M undefined173.27 M undefined0 undefined
2029e160.68 M undefined119.06 M undefined0 undefined
2028e103.77 M undefined70.04 M undefined0 undefined
2027e58.71 M undefined30.14 M undefined0 undefined
2026e31.02 M undefined6.45 M undefined5.7 M undefined
2025e13.06 M undefined-10.73 M undefined-123.81 M undefined
2024e8.47 M undefined-13.89 M undefined-123.81 M undefined
20230 undefined-13.48 M undefined-19.94 M undefined
20220 undefined-17.9 M undefined-38.73 M undefined
20210 undefined-15.64 M undefined-20.32 M undefined
20200 undefined-5.65 M undefined-12.01 M undefined
20190 undefined-1.21 M undefined-91,300 undefined
20180 undefined-599,100 undefined1.04 M undefined
20170 undefined-343,900 undefined123,800 undefined
20160 undefined-3,100 undefined-3,100 undefined

180 Life Sciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (k)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
000000008133158103160223
---------62.50138.4687.1077.5955.3439.38
---------------
000000000000000
000-1-5-15-17-13-13-1063070119173
---------162.50-76.9219.3551.7267.9674.3877.58
0010-12-20-38-19-123-12350000
-----66.6790.00-50.00547.37--104.07----
34.124.839.111.147.882.5100379.10000000
---------------
Details

Keystats

Revenue and Growth

The 180 Life Sciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the 180 Life Sciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (k)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
0.070.430.270.552.118.236.971.98
00000000
00000000
00000000
00.0400.051.112.281.341.21
0.070.470.270.63.2210.518.313.19
00000000
0116.59118.1711.880000
00000000
000014.6214.5310.721.62
000036.936.9900
1730000000
0.17116.59118.1711.8851.5251.5110.721.62
0.24117.06118.4412.4854.7462.0219.034.81
               
0107.83108.870.350000
0.034.883.843.9378.01107.18121.64130.12
-00.121.161.07-48.36-68.68-107.41-127.34
0000637817-2,886-2,901
00000000
0.02112.83113.875.3530.2939.3211.34-0.13
0.080.030.10.278.750.591.82.16
00004.611.982.471.87
00.180.450.84.4415.220.080
0.14002.072.70.0800
00000.971.831.311.03
0.220.210.553.1321.4619.75.665.06
0000114483120
00003.673.642.620.31
04.034.034.030000
04.034.034.033.783.692.650.33
0.224.234.577.1525.2523.398.315.39
0.24117.06118.4412.555.5362.7119.655.26
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of 180 Life Sciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand 180 Life Sciences's financial health and stability.

Assets

180 Life Sciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that 180 Life Sciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of 180 Life Sciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into 180 Life Sciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (k)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
001,0000-10,000-20,000-38,000-19,000
00000000
0000000-2
00002-820
00-2-1492411
00000000
00000000
000-1-3-19-12-10
00000000
0-115010814000
0-115010814000
00000000
0001,0000000
01120-108-826126
01160-106-825105
04000-2-10
00000000
000026-1-4
0-0.5-0.79-1.45-3.87-19.37-12.13-10.92
00000000

180 Life Sciences stock margins

The 180 Life Sciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of 180 Life Sciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for 180 Life Sciences.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the 180 Life Sciences's sales revenue. A higher gross margin percentage indicates that the 180 Life Sciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the 180 Life Sciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the 180 Life Sciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the 180 Life Sciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the 180 Life Sciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the 180 Life Sciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

180 Life Sciences Margin History

180 Life Sciences Gross margin180 Life Sciences Profit margin180 Life Sciences EBIT margin180 Life Sciences Profit margin
2030e0 %77.5 %0 %
2029e0 %74.1 %0 %
2028e0 %67.49 %0 %
2027e0 %51.34 %0 %
2026e0 %20.78 %18.37 %
2025e0 %-82.17 %-948 %
2024e0 %-163.93 %-1,461.39 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %

180 Life Sciences Stock Sales Revenue, EBIT, Earnings per Share

The 180 Life Sciences earnings per share therefore indicates how much revenue 180 Life Sciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue 180 Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates 180 Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of 180 Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 180 Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

180 Life Sciences Revenue, EBIT and net profit per share

Date180 Life Sciences Sales per Share180 Life Sciences EBIT per share180 Life Sciences Earnings per Share
2030e5.53 undefined0 undefined0 undefined
2029e3.97 undefined0 undefined0 undefined
2028e2.56 undefined0 undefined0 undefined
2027e1.45 undefined0 undefined0 undefined
2026e0.77 undefined0 undefined0.14 undefined
2025e0.32 undefined0 undefined-3.06 undefined
2024e0.21 undefined0 undefined-3.06 undefined
20230 undefined-35.55 undefined-52.59 undefined
20220 undefined-178.98 undefined-387.26 undefined
20210 undefined-189.59 undefined-246.36 undefined
20200 undefined-118.16 undefined-251.19 undefined
20190 undefined-108.91 undefined-8.23 undefined
20180 undefined-15.32 undefined26.61 undefined
20170 undefined-13.87 undefined4.99 undefined
20160 undefined-0.09 undefined-0.09 undefined

180 Life Sciences business model

180 Life Sciences Corp is a US biotechnology company that focuses on the development of treatments for chronic inflammatory diseases. The company was founded in 2018 and is headquartered in New York City. 180 Life Sciences is one of the most popular companies on Eulerpool.com.

180 Life Sciences SWOT Analysis

Strengths

180 Life Sciences Corp operates in various segments of the healthcare industry, including drug discovery and development, thereby reducing the reliance on a single sector.

With a dedicated team of experienced scientists and researchers, the company possesses strong research and development capabilities, allowing for the discovery of novel therapies and treatments.

180 Life Sciences Corp has established strategic partnerships with leading pharmaceutical companies and research institutions, enabling access to resources, expertise, and potential collaborations.

Weaknesses

The company may face challenges in gaining market share due to limited brand recognition and a relatively smaller customer base compared to well-established competitors.

180 Life Sciences Corp heavily relies on external funding sources, such as grants and partnerships, to support its research and development activities, which may present financial risks if such funding becomes unavailable or insufficient.

The company operates in a heavily regulated industry, subject to stringent regulatory requirements and lengthy clinical trial processes, which can increase costs and prolong time to market for new therapies.

Opportunities

The increasing prevalence of various diseases and conditions, coupled with the rising demand for more effective treatment options, presents significant opportunities for 180 Life Sciences Corp to capitalize on its innovative therapeutics.

As emerging markets continue to experience rapid economic growth and improvements in healthcare infrastructure, expanding the company's presence in these markets can unlock new revenue streams and a wider customer base.

Rapid advancements in technologies, such as genomics, AI, and precision medicine, provide opportunities for 180 Life Sciences Corp to leverage these tools in drug discovery, development, and personalized medicine, leading to enhanced therapies and treatments.

Threats

The healthcare industry is highly competitive, with larger pharmaceutical companies and biotech firms actively competing for market share and resources. This competitive landscape may pose challenges for 180 Life Sciences Corp in terms of securing funding, attracting talent, and gaining market acceptance.

Changes in regulations and government policies regarding drug approval, pricing, and reimbursement can impact the company's profitability and hinder market entry of new therapies, posing threats to 180 Life Sciences Corp's operations.

The company's success relies on obtaining and protecting intellectual property rights for its therapies and products. Intellectual property infringement or challenges from competitors can negatively impact its market position and revenues.

180 Life Sciences Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

180 Life Sciences historical P/E ratio, EBIT multiple, and P/S ratio

180 Life Sciences shares outstanding

The number of shares was 180 Life Sciences in 2023 — This indicates how many shares 379,100 is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue 180 Life Sciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates 180 Life Sciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of 180 Life Sciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating 180 Life Sciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

180 Life Sciences stock splits

In 180 Life Sciences's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for 180 Life Sciences.

180 Life Sciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20223.88 -26.6  (-786.27 %)2022 Q3
6/30/2022-50.39 34.2  (167.87 %)2022 Q2
3/31/2022-50.39 19  (137.71 %)2022 Q1
12/31/2021-50.39 19  (137.71 %)2021 Q4
9/30/2021-46.51 -41.8  (10.13 %)2021 Q3
1

180 Life Sciences shareholders

%
Name
Stocks
Change
Date
0.17432 % Feldmann (Marc)70,53257,3289/5/2024
0.01549 % Tower Research Capital LLC6,2692,8266/30/2024
0.00870 % Woody (James N)3,52114/29/2024
0.00719 % McGovern (Donald A Jr.)2,9101,3269/4/2023
0.00626 % Steinman (Lawrence)2,53414/29/2024
0.00453 % Marrone (Pamela G)1,8341,1789/4/2023
0.00365 % Rothbard (Jonathan B Ph.D.)1,47504/29/2024
0.00322 % Gold (Lawrence Marshall)1,3021,1299/4/2023
0.00317 % Ray (Russell T)1,2841,1299/4/2023
0.00185 % BlackRock Institutional Trust Company, N.A.75006/30/2024
1
2
3
4
...
5

180 Life Sciences Executives and Management Board

Dr. James Woody(80)
180 Life Sciences Chief Executive Officer, Director (since 2020)
Compensation 463,500
Mr. Ozan Pamir(32)
180 Life Sciences Chief Financial Officer, Company Secretary
Compensation 309,000
Dr. Jonathan Rothbard(71)
180 Life Sciences Chief Scientific Officer
Compensation 268,906
Sir Marc Feldmann(78)
180 Life Sciences Co-Executive Chairman of the Board (since 2020)
Compensation 225,000
Dr. Lawrence Steinman(75)
180 Life Sciences Co-Executive Chairman of the Board (since 2020)
Compensation 225,000
1
2

180 Life Sciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,230,450,340,770,44
1

Most common questions regarding 180 Life Sciences

What values and corporate philosophy does 180 Life Sciences represent?

180 Life Sciences Corp represents the values of innovation, dedication, and patient-centric care. With a corporate philosophy focused on advancing solutions for inflammatory diseases and fibrosis, the company is committed to improving the lives of patients worldwide. Through extensive research and development, 180 Life Sciences Corp aims to develop groundbreaking therapies and medical interventions that address unmet medical needs. This dedication to scientific excellence and patient well-being drives the company's pursuit of novel treatments and advancements in the field of life sciences.

In which countries and regions is 180 Life Sciences primarily present?

180 Life Sciences Corp is primarily present in the following countries and regions: United States of America (USA), Europe, and Canada.

What significant milestones has the company 180 Life Sciences achieved?

180 Life Sciences Corp has achieved several significant milestones. Firstly, the company successfully completed its reverse merger with KBLM Acquisition Corp., enabling it to become a publicly traded entity. Additionally, 180 Life Sciences Corp has made notable progress in its research and development activities, particularly in the areas of inflammation and fibrosis. The company has collaborated with world-renowned academic institutions and has established strong partnerships with leading experts in the field. Furthermore, 180 Life Sciences Corp has expanded its pipeline of potential therapeutics, advancing novel drug candidates that have shown promising preclinical results. These achievements highlight the company's dedication to developing innovative solutions for various diseases and improving patient outcomes.

What is the history and background of the company 180 Life Sciences?

180 Life Sciences Corp is a pharmaceutical company focused on developing and commercializing innovative therapies for inflammatory diseases and fibrosis. Founded in [year], the company has a strong dedication to improving patient outcomes by targeting the underlying mechanisms of these conditions. With a robust pipeline of potential treatments, including clinical-stage drug candidates, 180 Life Sciences Corp strives to address unmet medical needs and make a positive impact in the field of healthcare. Through extensive research and collaborations, the company aims to revolutionize treatment options and enhance the quality of life for individuals suffering from inflammatory diseases and fibrosis.

Who are the main competitors of 180 Life Sciences in the market?

Some of the main competitors of 180 Life Sciences Corp in the market include biopharmaceutical companies such as AbbVie Inc., Johnson & Johnson, Pfizer Inc., and Novartis AG. These companies also focus on developing and commercializing innovative therapies in the healthcare sector. However, 180 Life Sciences Corp distinguishes itself through its dedication to advancing novel treatments for inflammatory diseases and fibrosis conditions. With its unique research and development efforts, 180 Life Sciences Corp aims to stand out in the market and provide innovative solutions for patients worldwide.

In which industries is 180 Life Sciences primarily active?

180 Life Sciences Corp is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of 180 Life Sciences?

The business model of 180 Life Sciences Corp is focused on the development and commercialization of novel pharmaceutical products in the field of inflammatory diseases and fibrosis. The company aims to address unmet medical needs by identifying and advancing potential therapies through rigorous research and clinical trials. With a specialized focus on the development of targeted therapies, 180 Life Sciences Corp strives to improve patient outcomes and quality of life. By leveraging scientific expertise and strategic collaborations, the company aims to bring innovative and effective treatments to market, benefiting both patients and stakeholders in the healthcare industry.

What is the P/E ratio of 180 Life Sciences 2024?

The 180 Life Sciences P/E ratio is -0.01.

What is the P/S ratio of 180 Life Sciences 2024?

The 180 Life Sciences P/S ratio is 0.13.

What is the Quality Investing of 180 Life Sciences?

The Quality Investing for 180 Life Sciences is 3/10.

What is the revenue of 180 Life Sciences 2024?

The expected 180 Life Sciences revenue is 8.47 M USD.

How high is the profit of 180 Life Sciences 2024?

The expected 180 Life Sciences profit is -123.81 M USD.

What is the business model of 180 Life Sciences

180 Life Sciences Corp is a biopharmaceutical company based in the UK that develops innovative technologies for the treatment of inflammatory diseases. The company aims to significantly improve the quality of life for patients with chronic inflammatory conditions such as arthritis and fibromyalgia. The company follows a diversified business model that focuses on several areas. The main areas of the company include: - Research and development: 180 Life Sciences Corp conducts extensive research and development to develop innovative and effective drugs for the treatment of inflammatory diseases. The company has made significant progress in the areas of drug design and drug delivery systems. - Collaboration with strategic partners: The company forms targeted partnerships with leading pharmaceutical companies to enable commercialization of its products. 180 Life Sciences Corp collaborates closely with the University of Oxford and the Ferraresi Foundation to develop new technologies and conduct research activities. - Licensing: The company licenses its technologies and products to other companies. An example of this is the licensing of its technology for the production of transdermal patches to the pharmaceutical company Procter & Gamble. The products currently being developed by 180 Life Sciences Corp target the treatment of inflammatory diseases. The company's leading drug is a synthetic cannabidiol (CBD) product called SLS-002. This product is suitable for the treatment of inflammation and pain associated with arthritis and fibromyalgia. The company is also developing an inhalation device for the administration of cannabinoids. This device is intended to deliver the medication quickly and accurately to the lungs, increasing effectiveness and reducing necessary dosages. 180 Life Sciences Corp has also developed a technology for the production of transdermal patches. These patches are capable of delivering active ingredients directly through the skin, ensuring more effective absorption of the medication into the body. The company has entered into a licensing agreement with Procter & Gamble to utilize the transdermal patch technology. Overall, 180 Life Sciences Corp follows a promising business model based on a wide range of technologies and products for the treatment of inflammatory diseases. The company is working hard to further develop its technologies and establish new partnerships with other companies to bring its products to market.

What is the 180 Life Sciences dividend?

180 Life Sciences pays a dividend of 0 USD distributed over payouts per year.

How often does 180 Life Sciences pay dividends?

The dividend cannot currently be calculated for 180 Life Sciences or the company does not pay out a dividend.

What is the 180 Life Sciences ISIN?

The ISIN of 180 Life Sciences is US68236V1044.

What is the 180 Life Sciences WKN?

The WKN of 180 Life Sciences is A2QJX5.

What is the 180 Life Sciences ticker?

The ticker of 180 Life Sciences is ATNF.

How much dividend does 180 Life Sciences pay?

Over the past 12 months, 180 Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, 180 Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of 180 Life Sciences?

The current dividend yield of 180 Life Sciences is .

When does 180 Life Sciences pay dividends?

180 Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of 180 Life Sciences?

180 Life Sciences paid dividends every year for the past 0 years.

What is the dividend of 180 Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is 180 Life Sciences located?

180 Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von 180 Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of 180 Life Sciences from 11/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/10/2024.

When did 180 Life Sciences pay the last dividend?

The last dividend was paid out on 11/10/2024.

What was the dividend of 180 Life Sciences in the year 2023?

In the year 2023, 180 Life Sciences distributed 0 USD as dividends.

In which currency does 180 Life Sciences pay out the dividend?

The dividends of 180 Life Sciences are distributed in USD.

All fundamentals about 180 Life Sciences

Our stock analysis for 180 Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of 180 Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.